Ampio Pharm Performance
| AMPEDelisted Stock | USD 0.24 0.01 4.35% |
The firm shows a Beta (market volatility) of -0.0117, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Ampio Pharm are expected to decrease at a much lower rate. During the bear market, Ampio Pharm is likely to outperform the market. Ampio Pharm right now shows a risk of 0.0%. Please confirm Ampio Pharm sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Ampio Pharm will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ampio Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Ampio Pharm is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 12.7 M | |
| Free Cash Flow | -8.6 M |
Ampio |
Ampio Pharm Relative Risk vs. Return Landscape
If you would invest 24.00 in Ampio Pharm on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Ampio Pharm or generate 0.0% return on investment over 90 days. Ampio Pharm is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Ampio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ampio Pharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ampio Pharm's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Ampio Pharm, and traders can use it to determine the average amount a Ampio Pharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| AMPE |
Based on monthly moving average Ampio Pharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ampio Pharm by adding Ampio Pharm to a well-diversified portfolio.
Ampio Pharm Fundamentals Growth
Ampio Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Ampio Pharm, and Ampio Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ampio Pink Sheet performance.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | (3.33 M) | ||||
| Shares Outstanding | 1.14 M | ||||
| Price To Earning | 28.57 X | ||||
| Price To Book | 0.21 X | ||||
| EBITDA | (8.63 M) | ||||
| Cash And Equivalents | 23.25 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 274 K | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 4.03 X | ||||
| Cash Flow From Operations | (8.56 M) | ||||
| Earnings Per Share | (10.66) X | ||||
| Total Asset | 5.74 M | ||||
| Retained Earnings | (242.53 M) | ||||
| Current Asset | 29.23 M | ||||
| Current Liabilities | 5.52 M | ||||
About Ampio Pharm Performance
By analyzing Ampio Pharm's fundamental ratios, stakeholders can gain valuable insights into Ampio Pharm's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ampio Pharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ampio Pharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19 and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Ampio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 18 people.Things to note about Ampio Pharm performance evaluation
Checking the ongoing alerts about Ampio Pharm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Ampio Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ampio Pharm is not yet fully synchronised with the market data | |
| Ampio Pharm has some characteristics of a very speculative penny stock | |
| Ampio Pharm has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ampio Pharm currently holds about 23.25 M in cash with (8.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. |
- Analyzing Ampio Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ampio Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Ampio Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ampio Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ampio Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ampio Pharm's pink sheet. These opinions can provide insight into Ampio Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Ampio Pink Sheet
If you are still planning to invest in Ampio Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ampio Pharm's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |